Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

  • Dimitrios Pectasides1Email author,
  • George Papaxoinis1,
  • Konstantine T Kalogeras2, 3,
  • Anastasia G Eleftheraki4,
  • Ioannis Xanthakis2,
  • Thomas Makatsoris5,
  • Epaminondas Samantas6,
  • Ioannis Varthalitis7,
  • Pavlos Papakostas8,
  • Nikitas Nikitas9,
  • Christos N Papandreou10,
  • George Pentheroudakis11,
  • Eleni Timotheadou2,
  • Angelos Koutras5,
  • Joseph Sgouros6,
  • Dimitrios Bafaloukos12,
  • George Klouvas13,
  • Theofanis Economopoulos14,
  • Konstantinos N Syrigos15 and
  • George Fountzilas2
BMC Cancer201212:271

DOI: 10.1186/1471-2407-12-271

Received: 4 September 2011

Accepted: 29 June 2012

Published: 29 June 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
4 Sep 2011 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
14 Jan 2012 Reviewed Reviewer Report - Lara Lipton
4 Apr 2012 Reviewed Reviewer Report - Wei Chua
6 May 2012 Author responded Author comments - George Papaxoinis
Resubmission - Version 3
6 May 2012 Submitted Manuscript version 3
Publishing
29 Jun 2012 Editorially accepted
29 Jun 2012 Article published 10.1186/1471-2407-12-271

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Oncology Section, Second Department of Internal Medicine, “Hippokration” Hospital, University of Athens School of Medicine
(2)
Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine
(3)
Translational Research Section, Hellenic Cooperative Oncology Group, Data Office
(4)
Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office
(5)
Division of Oncology, Department of Medicine, University Hospital of Patras
(6)
Third Department of Medical Oncology, Agii Anargiri Cancer Hospital
(7)
Oncology Department, General Hospital of Chania
(8)
Department of Medical Oncology, Hippokration Hospital
(9)
Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine
(10)
Department of Internal Medicine, Oncology Section, Larissa University Hospital
(11)
Department of Medical Oncology, Ioannina University Hospital
(12)
First Department of Medical Oncology, Metropolitan Hospital
(13)
Second Department of Medical Oncology, Metropolitan Hospital
(14)
Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital
(15)
Oncology Unit, Third Department of Medicine, Athens Medical School, Sotiria General Hospital

Advertisement